Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026
Key Highlights
- ➤TNX-801 oral presentation scheduled for October 21 at World Vaccine Congress Europe
- ➤Tonix-led vectored vaccine working group session scheduled for October 20
- ➤TNX-801 expected to enter Phase 1 in 2027 pending FDA IND clearance
- ➤TNX-801 remains pre-IND and pre-clinical for mpox and smallpox prevention
Expert Statements
Farooq Nasar, Director, Virology, Research and Development Center, Tonix Pharmaceuticals
“TNX-801 Vaccine Platform Safety and Efficacy”
Sina Bavari, Executive Vice President, Infectious Disease, Research and Development Center, Tonix Pharmaceuticals
“Vectored Vaccine Platforms: From Design to Improving Efficacy”
Gabriella Worwa, Study Director, Research and Development Center, Tonix Pharmaceuticals
“Vectored Vaccine Platforms: From Design to Improving Efficacy”
Matilu Mwau, Senior Principal Clinical Research Scientist and Professor of Infectious Diseases, Kenya Medical Research Institute
“Vectored Vaccine Platforms: From Design to Improving Efficacy”
BERKELEY HEIGHTS, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced an oral presentation on TNX-801, a live, attenuated, minimally replicative investigational vaccine platform based on horsepox virus to protect against mpox and other infectious diseases, and a working group session led by Tonix, “Vectored Vaccine Platforms: From Design to Improving Efficacy,” at the World Vaccine Congress Europe held in Amsterdam, Netherlands on October 19-21, 2026.
TNX-801 Presentation Details Title: TNX-801 Vaccine Platform Safety and Efficacy Date & Time: Oct. 21, 2026, 1:15 p.m. CEST Session Category: Emerging & Infectious Diseases Presenter: Farooq Nasar, Ph.D., MPH, Director, Virology, Research and Development Center (RDC), Tonix Pharmaceuticals
Get started
Create a free account to read the full story.